Evidence map›Paper›PMID 38287266›Full record

ArticleBMC cancer2024

Prognostic marker CXCL5 in glioblastoma polyformis and its mechanism of immune invasion.

Wangyang Yu, Minfeng Zhou, Huifang Niu, Jinxiao Li, Qiumeng Li, Xiaoyun Xu, Fengxia Liang, Chen Rui

Open access · goldAbstract read
In one paragraph

Article in BMC cancer, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.9field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 2 citations in OpenAlex.

  1. [Journal of neuro-oncology · 2026
    Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Wangyang Yu *Union Hospital Affiliated to Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Minfeng Zhou *Union Hospital Affiliated to Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Huifang Niu *College of Food Science and Technology, Huazhong Agricultural University, Wuhan, China.
Jinxiao LiUnion Hospital Affiliated to Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Qiumeng LiUnion Hospital Affiliated to Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Xiaoyun XuCollege of Food Science and Technology, Huazhong Agricultural University, Wuhan, China. xuxiaoyun@mail.hzau.edu.cn.
Fengxia LiangSchool of Acupuncture and Bone Injury, Hubei University of Chinese Medicine, Wuhan, China. fxliang5@hotmail.com.
Chen RuiUnion Hospital Affiliated to Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China. unioncr@163.com.
Wuhan Union Hospital · CNHuazhong Agricultural University · CNHubei University of Chinese Medicine · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Glioblastoma multiforme (GBM) is the most aggressive brain cancer with a poor prognosis. Therefore, the correlative molecular markers and molecular mechanisms should be explored to assess the occurrence and treatment of glioma.WB and qPCR assays were used to detect the expression of CXCL5 in human GBM tissues. The relationship between CXCL5 expression and clinicopathological features was evaluated using logistic regression analysis, Wilcoxon symbolic rank test, and Kruskal-Wallis test. Univariate, multivariate Cox regression and Kaplan-Meier methods were used to assess CXCL5 and other prognostic factors of GBM. Gene set enrichment analysis (GSEA) was used to identify pathways associated with CXCL5. The correlation between CXCL5 and tumor immunoinfiltration was investigated using single sample gene set enrichment analysis (ssGSEA) of TCGA data. Cell experiments and mouse subcutaneous transplanted tumor models were used to evaluate the role of CXCL5 in GBM. WB, qPCR, immunofluorescence, and immunohistochemical assays showed that CXCL5 expression was increased in human GBM tissues. Furthermore, high CXCL5 expression was closely related to poor disease-specific survival and overall survival of GBM patients. The ssGSEA suggested that CXCL5 is closely related to the cell cycle and immune response through PPAR signaling pathway. GSEA also showed that CXCL5 expression was positively correlated with macrophage cell infiltration level and negatively correlated with cytotoxic cell infiltration level. CXCL5 may be associated with the prognosis and immunoinfiltration of GBM.

Indexed as

Brain NeoplasmsGlioblastomaAnimalsChemokine CXCL5HumansMiceNeoplastic ProcessesPrognosisSignal TransductionChemokine CXCL5CXCL5 protein, humanBrain cancerCXCL5Glioblastoma multiforme (GBM)Immune invasionImmunoinfiltration

Identifiers

PMID38287266
PMCPMC10823677
OpenAlexW4391317545

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.